Transcranial Magnetic Stimulation
Since the 1980s, transcranial magnetic stimulation has been used to study the nerve fibers that carry information about movements from the brain to the spinal cord and onto the muscles. In the late 1990s physicians began to explore the therapeutic potential of transcranial magnetic stimulation for the treatment of a variety of diseases, with depression being the most thoroughly studied to date. Since then, more than 30 randomized, controlled trials studying transcranial magnetic stimulation as a treatment for depression have been published by investigators throughout the world1,2.
NeuroStar TMS (transcranial magnetic stimulation) Therapy was recently FDA-cleared for patients suffering from depression who have not achieved satisfactory improvement from prior antidepressant medications.* Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. TMS Therapy is a short outpatient procedure, performed in your psychiatrist’s office under their supervision while you remain awake and alert. The typical initial course of treatment is about 37 minutes daily over 4-6 weeks. Learn how it works.
About NeuroStar TMS Therapy
The NeuroStar TMS (transcranial magnetic stimulation) system, developed by Neuronetics, is the first and only non-systemic and non-invasive depression treatment cleared by the US Food and Drug Administration (FDA) for the treatment of patients with major depression who have not benefited from prior antidepressant treatment.*
NeuroStar TMS Therapy is:
- Non-invasive, meaning that it does not involve surgery. It does not require any anesthesia or sedation, as the patient remains awake and alert during the treatment.
- Non-systemic, meaning that it is not taken by mouth and does not circulate in the bloodstream throughout the body.
- Schutter, D. (2009). “Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis.” Psychological Medicine 39: 65-75.
- Data on file.
Clinical trials have proven the effectiveness of NeuroStar TMS Therapy® in treating patients with major depression who have not benefited from prior antidepressant medication.* In clinical trials NeuroStar TMS Therapy was studied in adult patients suffering from Major Depressive Disorder, all of whom had not received satisfactory improvement with previous antidepressant medication.
In clinical trials, indicated patients had been treated with a median of four antidepressant medication attempts, one of which was at an adequate dose and duration.
Neurostar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.
NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant treatment. Its effectiveness has also not been established in patients who have failed to receive benefit from two or more prior antidepressant medications at minimal effective dose and duration in the current episode.
An Effective Option for Treating Major Depressive Disorder
In a controlled clinical trial comparing active treatment with the NeuroStar TMS Therapy® system to an inactive device, patients treated with active NeuroStar TMS Therapy experienced a 22.1% average reduction of their depression symptoms, compared to a 9% average reduction of depression symptoms in patients receiving inactive treatment.1
Patients treated with NeuroStar® also experienced significant improvement in anxiety and physical symptoms (such as appetite changes, aches and pains, and lack of energy) associated with depression.2
In a study most like real world clinical practice where all patients received active treatment, approximately half of the patients treated with NeuroStar TMS Therapy experienced significant improvement in their depression symptoms. About a third of the patients treated with NeuroStar TMS Therapy experienced complete symptom relief at the end of six weeks.2
- Data on file.
- Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharm Bull. 2009, 42(2): 5-38